BrightGene Bio-medical Technology(SH:688166) GLP1减重宝典·2025-07-17 10:44Core Viewpoint - The article discusses the initiation of a Phase III clinical trial for BGM0504, a drug developed by Borui Pharmaceutical for the treatment of type 2 diabetes, highlighting its potential efficacy and safety compared to semaglutide [2][4]. Group 1: Clinical Trial Details - The Phase III clinical trial is a randomized, open-label study comparing the subcutaneous injection of BGM0504 with weekly semaglutide in conjunction with metformin for type 2 diabetes patients [4]. - The trial will take place in Indonesia and aims to recruit 477 participants, with the primary endpoint being the change in glycated hemoglobin (HbA1c) from baseline [4]. Group 2: Drug Profile - BGM0504 is a dual agonist of GLP-1 and GIP receptors, designed to activate both GIP and GLP-1 downstream pathways, which may improve blood sugar control, promote weight loss, and treat metabolic dysfunction-related fatty liver disease (MASH, formerly known as NASH) [4]. - The drug shows significant potential in treating various metabolic diseases [4]. Group 3: Current Progress - According to the Insight database, BGM0504 has initiated four Phase III clinical trials, with three conducted in China (two for type 2 diabetes and one for obesity) and one in Indonesia (for type 2 diabetes) [6].